AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “buy” rating reissued by stock analysts at FBR & Co in a research note issued on Friday. They currently have a $3.00 price target on the biopharmaceutical company’s stock. FBR & Co’s target price suggests a potential upside of 35.14% from the company’s current price.

Several other research firms have also issued reports on AVEO. ValuEngine raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 24th. Piper Jaffray Companies set a $2.00 price objective on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Finally, Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd.

Shares of AVEO Pharmaceuticals (AVEO) remained flat at $2.22 during trading on Friday. 2,922,250 shares of the company were exchanged. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $2.42. The firm’s market cap is $245.00 million. The stock’s 50-day moving average is $0.89 and its 200-day moving average is $0.73.

AVEO Pharmaceuticals (NASDAQ:AVEO) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). AVEO Pharmaceuticals had a negative net margin of 728.85% and a negative return on equity of 836.92%. The company had revenue of $2.53 million during the quarter. On average, analysts expect that AVEO Pharmaceuticals will post ($0.44) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/07/03/aveo-pharmaceuticals-inc-nasdaqaveo-given-a-3-00-price-target-at-fbr-co.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co purchased a new position in shares of AVEO Pharmaceuticals during the first quarter valued at $184,000. UBS Oconnor LLC purchased a new position in shares of AVEO Pharmaceuticals during the first quarter valued at $291,000. Sabby Management LLC purchased a new position in shares of AVEO Pharmaceuticals during the first quarter valued at $513,000. Renaissance Technologies LLC increased its position in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares during the period. Finally, Sphera Funds Management LTD. purchased a new position in shares of AVEO Pharmaceuticals during the first quarter valued at $1,711,000. Institutional investors and hedge funds own 50.96% of the company’s stock.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.